UOC
PFE icon

UBS O'Connor’s Pfizer PFE Stock Holding History

UBS O'Connor’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-6,062,081
Closed -$40M – 532
2013
Q2 		$40M Buy
+6,062,081
New +$167M 0.75% 33

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS O'Connor's PFE Position: Q4 2025 in Review

UBS O'Connor opened a new position in Pfizer (PFE) in Q4 2025: 102,623 shares worth $2.56M. The stake represents 0.08% of the portfolio and ranks #87 among its holdings. This is a return to the name: UBS O'Connor previously reported a position in PFE as recently as Q4 2014.

UBS O'Connor first reported a position in PFE in Q2 2013 and has held it in 3 quarters since. The position peaked at $167M in Q2 2013. 2,907 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • UBS O'Connor held 102,623 shares of Pfizer worth $2.56M as of Q4 2025.
  • Pfizer was a new UBS O'Connor position in Q4 2025.
  • Pfizer made up 0.08% of UBS O'Connor's portfolio in Q4 2025, its #87 holding.
  • UBS O'Connor first reported a position in Pfizer in Q2 2013 and has held it in 3 quarters since.
  • UBS O'Connor's Pfizer position peaked at $167M in Q2 2013.
  • 2,907 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.